UK markets close in 2 hours 28 minutes

  • FTSE 100

    7,567.63
    -40.45 (-0.53%)
     

  • FTSE 250

    18,195.33
    -84.09 (-0.46%)
     

  • AIM

    726.46
    +0.28 (+0.04%)
     

  • GBP/EUR

    1.1539
    +0.0006 (+0.06%)
     

  • GBP/USD

    1.2151
    -0.0050 (-0.41%)
     

  • Bitcoin GBP

    23,344.74
    +953.93 (+4.26%)
     

  • CMC Crypto 200

    607.79
    +29.03 (+5.02%)
     

  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     

  • DOW

    33,507.50
    -158.80 (-0.47%)
     

  • CRUDE OIL

    91.13
    +0.34 (+0.37%)
     

  • GOLD FUTURES

    1,850.50
    -15.60 (-0.84%)
     

  • NIKKEI 225

    31,759.88
    -97.72 (-0.31%)
     

  • HANG SENG

    17,809.66
    +436.66 (+2.51%)
     

  • DAX

    15,348.27
    -38.31 (-0.25%)
     

  • CAC 40

    7,116.30
    -18.76 (-0.26%)
     
Crypto Mile:

Crypto bosses pouring millions into anti-ageing tech to live longer

The longevity sector is experiencing increasing momentum as CEOs drive funding and research

Guidance for the 2023/24 financial year

Chemometec A/S
·1-min read
Chemometec A/S
Chemometec A/S

ANNOUNCEMENT NO. 242

13 September 2023


Guidance for the 2023/24 financial year

ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information.

For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million).

The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2023/24.


Additional information

Rasmus Kofoed, CEO
Tel.: (+45) 26 72 68 19

Niels Høy Nielsen, CFO
Tel.: (+45) 25 51 87 24


About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.